Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 46.9%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 5,200 shares, a decline of 46.9% from the November 15th total of 9,800 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 45,100 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On Avalo Therapeutics

Several large investors have recently bought and sold shares of AVTX. Affinity Asset Advisors LLC raised its position in Avalo Therapeutics by 350.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock valued at $561,000 after purchasing an additional 35,000 shares during the last quarter. Logos Global Management LP acquired a new position in Avalo Therapeutics in the 2nd quarter valued at about $6,722,000. RA Capital Management L.P. acquired a new position in Avalo Therapeutics in the 3rd quarter valued at about $9,186,000. Finally, Ikarian Capital LLC lifted its position in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after acquiring an additional 915,629 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock traded up $0.12 during mid-day trading on Friday, hitting $9.23. The company had a trading volume of 189,188 shares, compared to its average volume of 203,906. Avalo Therapeutics has a 1 year low of $3.95 and a 1 year high of $34.46. The business has a fifty day moving average of $11.16 and a 200 day moving average of $10.81.

Analyst Ratings Changes

Separately, HC Wainwright began coverage on Avalo Therapeutics in a research note on Thursday, October 24th. They issued a “neutral” rating on the stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.